Aim: To study the effect of peroxisome proliferator-actived receptor γ (PPARγ) ligands on cell proliferation and apoptosis in human renal carcinoma cell lines. Methods: The expression of PPARγ was investigated by reverse transcriptase polymerase chain reaction (RT-PCR), Western blot and immunohistochemistry. The effect of thiazolidinedione (TZD) PPARγ ligands on growth of renal cell carcinoma (RCC) cells was measured by MTT assay and flow cytometric analysis. Cell death ELISA, Hoechst 33342 fluorescent staining and DNA ladder assay were used to observe the effects of PPARγ ligands on apoptosis. Regulatory proteins of cell cycle and apoptosis were detected by Western blot analysis. Results: PPARγ was expressed at much higher levels in renal tumors than in the normal kidney (2.16±0.85 vs 0.90±0.73; P<0.01). TZD PPARγ ligands inhibited RCC cell growth in a dose-dependent manner with IC 50 values of 7.08 µmol/L and 11.32 µmol/L for pioglitazone, and 5.71 µmol/L and 8.38 µmol/L for troglitazone in 786-O and A498 cells, respectively. Cell cycle analysis showed a G 0 /G 1 arrest in human RCC cells following 24-h exposure to TZD. Analysis of cell cycle regulatory proteins revealed that TZD decreased the protein levels of proliferating cell nuclear antigen, pRb, cyclin D 1 , and Cdk4 but increased the levels of p21 and p27 in a timedependent manner. Furthermore, high doses of TZD induced massive apoptosis in renal cancer cells, with increased Bax expression and decreased Bcl-2 expression. Conclusion: TZD PPARγ ligands showed potent inhibitory effect on proliferation, and could induce apoptosis in RCC cells. These results suggest that ligands for PPARγ have potential antitumor effects on renal carcinoma cells.
Introduction
Peroxisome proliferator-activated receptor γ (PPARγ) belongs to the superfamily of nuclear hormone receptor transcription factors [1] [2] [3] . PPARγ forms a heterodimer with another nuclear receptor, retinoid X receptor α (RXRα) [4] . In the presence of their ligands, PPARγ/RXRα heterodimer binds to a specific DNA sequence designated peroxisome proliferating response element (PPRE) located in the promoter region of PPARγ target genes and modulates their transcription [5] . Thus far, hundreds of PPARγ target genes have been identified and most of them are involved in adipogenesis [6] , glucose metabolism [7] and angiogenesis [8] . Since the discovery of specific ligands for PPARγ, including synthetic antidiabetic thiazolidinediones (TZD) and endogenous 15-deoxy-D 12, 14 -PGJ2 (15dPGJ2) and some polyunsaturated fatty acids, accumulating evidence using many experimental systems suggests that PPARγ plays an important role in carcinogenesis in both adipose and nonadipose cells. It has been known that PPARγ expression is up-regulated in many tumor tissues and its ligands, including pioglitazone, troglitazone and roglitazone, can induce apoptosis and exert antiproliferative effects in human colon cancer [9] , breast cancer [10] , pituitary adenomas [11] , gastric cancer [12] and bladder cancer [13] . Moreover, PPARγ may play an important role in inducing cell differentiation or growth inhibition in patients with liposarcoma [14] and prostate cancer [15] . Therefore activation of PPARγ seems to be a potential approach for treatment of some malignant tumors.
Renal cell carcinoma (RCC) is the most common renal tumor and the third malignancy within urological oncology. It makes up approximately 2%-3% of all adult malignancies. At present, more than 50% of all RCC are found incidentally, which results in a high proportion of patients with progressive metastasis at the time of diagnosis [16, 17] . Surgery remains the only effective therapeutic option. Although combination of chemotherapy and/or radiotherapy might help in survival rate, it is considered to be of limited value for the treatment of RCC. Therefore, improvement of life span in patients with renal cell carcinoma greatly depends on the identification of novel treatment strategies. An alternative treatment may include activation of PPARγ, as PPARγ has been shown to be expressed in the kidney [18] , and its ligands can induce cell growth inhibition and terminal differentiation in many other maliganancies [9] [10] [11] [12] [13] [14] . In the present study, we examined the expression of PPARγ in human primary RCC and RCC cell lines, and determined the biological events of PPARγ activation in inducing RCC cell cycle arrest and apoptosis. We have also explored the molecular mechanism through which PPARγ agonists inhibit cell growth and induce cell death in RCC cell lines.
Materials and methods
Chemicals Pioglitazone and troglitazone were kindly gifted by Park-Davis Pharmaceutical Research (Ann Arbor, MI, USA) and Takeda Chemical Industries (Osaka, Japan). All other chemicals were purchased from Sigma (St Louis, MO, USA). Stock solutions of pioglitazone or troglitazone were made at 100 mmol/L concentration in dimethyl sulfoxide and added to the culture medium at the final concentration of less than 0.1%.
Cell lines and culture conditions Human RCC-derived cell lines 786-O and A498, human proximal tubular cell line (HK-2), and human mesangium cell line (HMCL) were cultured in Hepes-buffered RPMI-1640 medium (Gibco BRL, Grand Island, NY, USA) supplemented with 10% FBS, 100 kU/mL penicillin G, 100 g/L streptomycin, and 2 mmol/L l-glutamine in a humidified 5% CO 2 atmosphere at 37 ºC. The media were changed every 3 d, and the cells were separated by trypsinization using trypsin/edetic acid when they reached 90% confluence.
Tumor specimens and immunohistochemistry Specimens were obtained from 120 patients with RCC and 20 patients with normal kidney (NK) who underwent total nephroureterectomy as a result of ureteral cancer or trauma. All patients were treated at the Institute of Urology in Peking University between June 1999 and June 2001. No patients had received irriadiation or chemotherapy prior to surgery. Tumor samples with the highest nuclear grade were selected. All tissues were preserved in 10% formalin serially sectioned onto microscope slides with a thickness of 4 µmol/L. Sections were immunostained with polycolonal antibody to human PPARg (1:100, Santa Cruz Biotechonology, Santa Cruz, CA, USA) using avidin-biotin-complex-peroxidase and counterstained with hematoxylin. Negative control slides were prepared by omitting the primary antibody. The intensity of immunostaining and the ratio of the positive cells were roughly graded into four scores (0, 1, 2, 3, and 4) by two observers who did not know the origin of the samples on two occasions. The score 4 was defined as maximum intensity of immunostaining throughout the section, while the score 0 implied that staining was absent throughout the specimen.
Measurement of PPARγ γ γ γ γ mRNA by reverse transcrip- The effect of PPARγ ligands on cell proliferation of RCC cells was determined using MTT assay [13] . Briefly, cells of 0. Apoptosis assay Cytosolic histon-bound DNA fragments caused by apoptosis were detected using a cell death ELISA kit (Roche Applied Science, Mannheim, Germany) according to manufacturer's protocol. Briefly, 1×10
4 cells were seeded in a 96-well microplate and incubated for 4 h at 37 °C. Pioglitazone 0-100 µmol/L or troglitazone was added and incubated for 48 h. Cells were then lysed with lysis buffer for 30 minutes at 25 °C. Supernatant 20 µL was transferred into the streptavidin coated multiplate, 4 µL anti-histon-biotin and 4 µL anti-DNA-POD were added to each well, and the plate was shaken for 2 h. After being washed with incubation buffer, 100 µL ABTS (2,2'-Azino-di[3-ethylbenzthiazolinesulfonate]) solution was pipetted into each well. The absorbance was read immediately in a microplate reader (BIO-RAD, model 3550) at 405 nm. Furthermore, apoptosis of RCC cell lines induced by 70 µmol/L troglitazone or 80 µmol/L pioglitazone was also assayed using two other methods. Morphological changes resulting from apoptosis were determined by Hoechst 33342 staining. Cells suspended in PBS were stained with 2 mg/L Hoechst33342 and observed under fluorescence microscope using a blue filter. Cells showing cytoplasmic and nuclear shrinkage and chromatin condensation or fragmentation were defined as apoptotic cells. DNA fragmentation manifested as laddering in agarose gel was also examined. After drug treatment, the cells pellet was lysed in 10 mmol/L Tris-HCl pH 8.0, 150 mol/L NaCl, 10 mmol/L edetic acid and 0.5% SDS on ice for 10 min, and treated with RNase A and proteinase K for 1 h. Following DNA precipitation with ethanol and ammonium acetate at -20 °C for 10 h, DNA was dissolved in TE buffer, electrophoresed in 1.8% agarose gel, and visualized under UV light.
Western blot analysis Cells before and after drug treatment were extracted with lysis buffer containing 50 mmol/L Tris-HCL, pH 8.0, 150 mmol/L sodium chloride, 1% TritonX-100, 0.02% sodium azide, 100 mg/L phenylmethylsulfony fluoride and 1 mg/L aprotinin. The protein content in cell lysate was determined by bicichoninic acid assay using bovine serum albumin as the standard. Cell lysate containing 50-60 µg protein was resolved by SDS-polyacrylamide gel electrophoresis and electrophoretically transferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). The membrane was blotted by antibodies against human PPARγ (1:500), proliferating cell nuclear antigen (PCNA; 1:1500), pRb (1:1000), p21 (1:1000), p27 (1:1000), cyclinD 1 (1:1000), Cdk 4 (1:1000), Bcl-2 (1:1000) and Bax (1:800) (Santa Cruz Biotechnology). Blotted antibody was developed by horseradish peroxidase-conjugated secondary antibody and enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, Uppsala, Sweden).
Statistical analysis The experimental results shown were repeated twice or three times, unless otherwise indicated. Results are expressed as mean±SD. Statistical analysis was carried out using Student's t-test and one-way ANOVA. Significance was set at P<0.05. Statistical analyses were performed using SPSS10.0 (SPSS Inc, Chicago, IL, USA) 
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Discussion
PPARγ is a nuclear receptor transcription factor and plays an important role in many biological processes including adipogenesis, cell growth regulation, and cell differentiation. The synthetic TZD class of compounds, including pioglitazone and troglitazone, are originally developed as therapeu- tic agents for diabetes mellitus and have been recently found to be specific ligands for PPARγ with high affinity. In the past decade, evidence began to emerge suggesting TZD PPARγ agonists not only exert antidiabetic effect in type II diabetes mellitus but also induce cell growth arrest, apoptosis and terminal differentiation in many human malignant tumors including colon cancer, breast cancer, pituitary adenomas, pancreatic carcinoma and esophageal cancer [9] [10] [11] 19, 20] , suggesting PPARγ may be a potential therapeutic target for treatment of certain human cancers. The present study provides evidence that high expression of PPARγ was observed in human RCC tissues and cell lines, and activation of PPARγ resulted in G 0 /G 1 cell cycle arrest and apoptosis involved Bcl-2 pathway.
In the present study, we observed that PPARγ was abundantly expressed in almost all high-grade human RCC specimens (98.3%), and two RCC cell lines were examined. Its intracellular distribution was mainly localized in nuclear area. In contrast, although PPARγ immunostaining was also positive in most normal renal tissues, its expression was much lower than that in RCC tissues and limited in medullary collecting duct cells in the kidney. Furthermore, its subcellular localization was predominantly in the cytoplasm. The differ- ences of PPARγ in quantity and intracellular distribution between human RCC and normal kidney tissues may implicate an important role of PPARγ in tumorigenesis of renal cell carcinoma. Consistent with a previous study [21] , activation of PPARγ in two human RCC cell lines resulted in inhibition of RCC cell growth as assessed using MTT assay and Flow Cytometry. As seen in other tumor cells, treatment of RCC cells lines with pioglitazone and troglitazone for 24 h caused G 0 /G 1 phase arrest and blocked cells from entering the S phase [13, 19, [22] [23] [24] .
To explore the mechanism involved in PPARγ-induced cell growth arrest, RCC cells were treated with pioglitazone and troglitazone and expression of cell cycle proteins was examined. We observed a marked reduction in PCNA, pRb, Cdk4 and Cyclin D1 expression and a dramatic increase in p21 and p27 expression in TZD-treated RCC cells. Down-regulation of PCNA, a nuclear protein essential for DNA replication and repair by DNA polymerase δ [25] , is in agreement to the low proliferation rate observed in these treated RCC cells. Proliferation of eukaryotic cells is tightly regulated by expression and sequential activation of cell cycle-dependent cyclins, Cdks and CdkIs [26] . pRb, a key regulator of G 1 cell cycle progression, is phosphorylated by a set of Cyclin-Cdk complexes, such as the complexes of Cyclin D and Cdk4/6 or cyclin E and Cdk2 [27, 28] . In its dephosphorylated state, pRb binds to E2F and inhibits G 1 -S phase transi-tion. In contrast, phosphorylation of pRb causes breakdown of E2F/pRb complex, and initiates DNA synthesis. In the present study, Decreased expression of phosphorylated pRb was found in these treated cells. CdkIs are cell cycle regulatory molecules having negative effects on cell cycle machinery by binding to various cyclin-Cdk complexes and inhibiting their activities. In mammals, there are two structurally defined classes of CdkIs, the INK4 family and the KIP/CIP family [29] . The KIP/ CIP family, including p21 CIP , p27 KIP1 , and p57 KIP2 , interacts with cyclin E-Cdk2, cyclin D-Cdk4, cyclin D-Cdk6, and cyclin A-Cdk2 complexes, and inhibits their activities [28] . The decrease of cyclin D1 and Cdk4 and increased expression of CdkI proteins including p21 and p27 strongly suggest TZD PPARγ agonists induced the overexpression of the members of KIP/CIP family which sequentially inhibited the activities of cyclin D1-Cdk4 complex, the phosphorylation of pRb, and the G 1 -S phase transition. These findings are consistent with the observation that two TZD PPARγ agonists decreased cell proliferation in MTT assay and arrested cells in G 0 /G 1 phase by flow cytometry.
Cell cycle status and cell programmed death are usually closely associated [13] . Besides the cell cycle arrest, the inhibition of cell growth observed in RCC cells treated with pioglitazone and troglitazone may also be a result of the increase in apoptosis [30] . Cells failing to progress to mitosis phase are destined for apoptosis. TZD have been reported to be potent agents in inducing apoptosis in many human tumors including breast cancer, pituitary tumors and gastric cancer [10] [11] [12] . In the present study, we clearly demonstrated that at high concentrations PPARγ agonists pioglitazone and troglitazone caused marked apoptosis in human RCC cells as assessed by morphological change, DNA fragmentation and the cell death ELISA assay. These studies suggest that TZD may exert pro-apoptotic effect on human RCC cells.
Multiple pathways are involved in apoptosis including Bcl-2 system, fas/fasL pathway, and caspase cascade [31] [32] [33] . To explore the molecular mechanism through which TZD PPARγ agonist induces apoptosis in human RCC cells, we examined Bcl-2 and Bax expression following pioglitazone and troglitazone treatment in 786-O cells and A498 cells. We observed for the first time that activation of PPARγ by both TZD markedly decreased Bcl-2 protein expression but increased Bax protein expression. Because Bcl-2 protects cells from apoptosis, while the increase of Bax induces apoptosis [34, 35] , our findings suggest that decreased Bcl-2 expression and increased Bax expression may participate in TZD PPARγ agonist-induced apoptosis in human RCC cells.
PPARγ agonists, such as 15-dPGJ 2 , troglitazone, have been shown to possess effects not involving PPARγ [36, 37] , For instance, the potencies for inhibition of cholesterol synthesis by troglitazone is mechanistically distinct from the transcriptional regulation by PPARγ [38] . In the present study, low doses of TZD fail to induce RCC cell death. It has been reported that TZD promote T cell survival at doses that induce optimal PPARγ transcriptional activity [39] , and cell deaths induced by TZD always use concentrations of TZD several orders of magnitude higher than K D for PPARγ [39, 40] . Moreover, troglitazone could induce apoptosis of rat hepatoma cells, but rosiglitazone, a potent PPARγ agonist, did not have the same effect [41] , indicating that PPARγ independent pathways, such as TZD-induced loss of mitochondrial membrane potential [42] , may be involved in the mechanisms of TZD induced cell apoptosis. Furthermore, it has also been reported that PPARγ agonists could induce apoptosis in nonmalignant cells, including isolated rat mesangial cells [43] . Thus the mechanisms of anticaner effect of TZD need to be further explored.
In summary, the present study provides evidence that PPARγ is highly expressed in human renal cell carcinoma cells. Activation of PPARγ by TZD PPARγ agonists results in inhibition of cell proliferation, likely by arresting the cells in G 0 /G 1 cell cycle phase. In addition, PPARγ agonists also induce marked apoptosis partly through decreased Bcl-2 and enhanced Bax protein expression in human RCC cells. Additional research will need to be performed to explore the mechanism of TZD which induced cell apoptosis, and the potential therapeutic value of PPARγ agonists in renal cell carcinoma.
